Xencor

Xencor, Inc. is biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xencor reports strong earnings, focuses on innovative pipeline strategies

Xencor's strong financial performance and promising pipeline programs position it well for growth
Unique mechanisms and designs offer competitive advantages in oncology and autoimmune disease treatments
Challenges like revenue expectations and validation requirements are being addressed strategically
Opportunities for collaborations and program optimizations pave the way for future success

Xencor advances internal portfolio with strategic focus on impactful targets

Xencor's Q1 2023 Earnings Call highlighted progress in their internal development portfolio, welcoming a new Chief Development Officer and emphasizing innovative therapeutic formats.
While facing challenges in data updates and program differentiation, the company's strategic focus on impactful targets and early clinical development positions them for future success.
Opportunities lie in expanding therapeutic programs, leveraging royalties, and exploring new avenues for growth, signaling a promising trajectory for Xencor in the biopharmaceutical landscape.

Xencor reports robust Q2 earnings and pipeline advancements

Xencor's Q2 2023 earnings call showcased strong performance in royalties and collaborations
The company's diverse pipeline and focus on safety and selectivity present opportunities
Challenges include addressing safety concerns and finalizing regimen for advancement
Overall, Xencor remains optimistic about future updates and pipeline progress

Xencor reports robust Q3 earnings, advances novel oncology therapeutics

Xencor's Q3 earnings call highlighted a strong financial performance, strategic pipeline adjustments, and progress in developing novel antibody-based therapeutics for oncology. The company is focused on maintaining asset potential through royalty deals and advancing internal pipeline candidates targeting solid tumors.

Xencor reports robust clinical data for vudalimab in prostate cancer

Xencor's Q4 earnings call showcased strong clinical data for vudalimab in prostate cancer, highlighting its efficacy and safety profile. The company's strategic focus on T-cell engagers and XmAb bispecific technology positions it well for future growth and innovation in solid tumor targeting.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Xencor (XNCR) to Report a Decline in Earnings: What to Look Out for

Spectrum Pharma

These hidden gems have the potential to deliver significant returns to their shareholders over the long run.

2 Top Cancer Treatment Stocks To Watch In July

MONROVIA, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that the companies ha

Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced the presentation of new preclinical data from three XmAb® 2+1 bispecific antibody programs and its IL-12-Fc cytokine program during the second session of the American Association for Cancer Research (AACR) Virtual Annual Meeting. Poster presentations and audio descriptions are a

Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II

Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q1 2020 Results - Earnings Call Transcript

Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q4 2019 - Earnings Call Transcript

Xencor (XNCR) delivered earnings and revenue surprises of 9.62% and -47.76%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Reports Q4 Loss, Lags Revenue Estimates

Earnings Preview: Xencor (XNCR) Q4 Earnings Expected to Decline

Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q3 2019 Results - Earnings Call Transcript

Sr. Vice President & CFO of Xencor Inc (30-Year Financial, Insider Trades) John J Kuch (insider trades) sold 40,000 shares of XNCR on 08/21/2019 at an average price of $41.27 a share.

Xencor Inc (XNCR) Sr. Vice President & CFO John J Kuch Sold $1.7 million of Shares

Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q2 2019 Results - Earnings Call Transcript

Xencor (XNCR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Xencor (XNCR) Jumps: Stock Rises 7.4%

Xencor Inc. shares are trading higher after it was announced the company will replace HFF Inc in the S&P SmallCap 600 on July 2.

Xencor To Replace HFF In The S&P SmallCap 600, Shares Rise

Xencor gets FDA to remove the partial clinical hold for XmAb14045 to treat patients with relapsed/refractory acute myeloid leukemia.

Along With FDA Clinical Hold Being Lifted, Xencor Has Other Promising Drugs

Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q1 2019 Results - Earnings Call Transcript

News for Xencor Stock (XNCR)